SCHEMBL6181435

SCHEMBL6181435

CCN1CCCC(Oc2ccc([N+](=O)[O-])cc2)C1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
PARP1 P09874 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
HRH3 Q9Y5N1 2/20 0.45
LTA4H P09960 1/20 0.45
PTGS1 P23219 1/20 0.45
PTGS2 P35354 1/20 0.45
SIGMAR1 Q99720 1/20 0.44
CYP3A4 P08684 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
ACHE P22303 1/20 0.43
HPGD P15428 1/20 0.43
KMT2A Q03164 1/20 0.43
POLB P06746 1/20 0.42
KCNJ1 P48048 1/20 0.42
KCNH2 Q12809 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4348693 0.92 HRH3 (0.50) ALDH1A1KDM4ESMN1; SMN2PARP1HRH3
SCHEMBL9683693 0.86 ACHE (0.47) ALDH1A1KDM4ESMN1; SMN2TDP1HRH3
SCHEMBL9235807 0.84 HRH3 (0.61) ALDH1A1KDM4ESMN1; SMN2HRH3SIGMAR1
SCHEMBL5205810 0.83 ROCK1 (0.56) ACHEKCNH2
SCHEMBL3551073 0.83 ROCK1 (0.56) ACHEKCNH2
SCHEMBL3276264 0.83 KDM4E (0.46) ALDH1A1KDM4ESMN1; SMN2PARP1TDP1
SCHEMBL27720300 0.81 HRH3 (0.54) ALDH1A1KDM4ESMN1; SMN2HRH3SIGMAR1
SCHEMBL4365012 0.81 HRH3 (0.48) KDM4ESMN1; SMN2PARP1HRH3CYP3A4
SCHEMBL9231422 0.81 HRH3 (0.64) HRH3LTA4HPTGS1PTGS2SIGMAR1
SCHEMBL2320447 0.80 KDM4E (0.49) KDM4EPARP1HRH3CYP3A4CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1507530-B1 DIAMINOTHIAZOLES AND USE THEREOF AS CDK4 INHIBITORS HOFFMANN LA ROCHE (CH) 2005-11-02 EP disclosed
EP-1507530-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2005-02-23 EP disclosed
US-6818663-B2 AS INHIBITORS OF CYCLIN-DEPENDENT KINASE 4 (CDK4); ANTIPROLIFERATIVE AGENTS; FOR THERAPY OF CANCER, TUMORS HOFFMANN-LA ROCHES 2004-11-16 US disclosed
US-20040006058-A1 DIAMINOTHIAZOLES CHU XIN-JIE (US) 2004-01-08 US disclosed
WO-2003097048-A1 DIAMINOTHIAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006058-A1 DIAMINOTHIAZOLES CDK4, CDK1, CDK2 ALDH1A1 1361/4885KDM4E 377/4885SMN1; SMN2 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.